Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. - Wikidata - awgldk - TriplyDB

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

http://www.wikidata.org/entity/Q34664129

about

Recent developments in receptor tyrosine kinases targeted anticancer therapy Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer.The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers.Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin.Perspective on the dynamics of cancer.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.

P2860

Q26751331-54AFF000-4E87-44FC-B97E-24E9852E0A2D Q28066819-06131898-F33B-4AD4-B7D4-AD7465AF6F54 Q28551145-BDD86DE2-A232-4E23-A01A-A53AF50DDC3E Q35741610-FFB1FFC8-A709-4E1B-821F-B1C3A801C707 Q35829723-56F5F91F-D392-4D9F-A00E-C3E1F002F5C6 Q36677415-34748ABE-F184-4709-993D-815B10D88534 Q36777139-A0300575-FD28-45ED-9262-59B5BA2A478A Q36998301-2B3102E0-E6FF-40AB-A996-4E6D57ECDE3C Q38694128-F24D5708-AB83-413C-939D-8DDDEF616CAC Q38695293-CE285625-7560-4886-8E6D-5E7512568DCD Q38847931-2F4A33C8-5867-4839-8328-83B0B187088C Q38878623-BB462FBE-9F56-4C72-A1D3-ABF5C17C8D42 Q42284422-93B70367-B7CE-47F1-9670-F2641F22FAC2 Q47103332-E4527B0C-37E5-40EA-925B-584BE64DE356 Q49887925-B7D24923-D45D-4933-8BCA-E062125DE5F4

P2860

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

http://www.wikidata.org/entity/Q34664129

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Personalized drug combinations ...... n HER2-positive breast cancer.

@ast

Personalized drug combinations ...... n HER2-positive breast cancer.

@en

Personalized drug combinations ...... n HER2-positive breast cancer.

@nl

type

label

Personalized drug combinations ...... n HER2-positive breast cancer.

@ast

Personalized drug combinations ...... n HER2-positive breast cancer.

@en

Personalized drug combinations ...... n HER2-positive breast cancer.

@nl

prefLabel

Personalized drug combinations ...... n HER2-positive breast cancer.

@ast

Personalized drug combinations ...... n HER2-positive breast cancer.

@en

Personalized drug combinations ...... n HER2-positive breast cancer.

@nl

P1433

Q34664129-F4E1AD5F-8280-467E-9EEC-99399B3B78CA

P1476

Q34664129-2285ED47-F7DA-48A8-AFA0-67082F77D2A5

P2093

Q34664129-AF821BA3-9327-41E3-A079-64C9335CB6B0

Q34664129-CF7AE760-B7B6-4F46-9BB7-45258C52915E

Q34664129-DCF56751-705F-40D2-A0F8-234580C967C9

P2860

Q34664129-0070AD09-76F4-40C6-AE47-0868507CEF0C

Q34664129-05C4B498-AF71-4142-98DB-B76E3E1D71A5

Q34664129-070DB3CC-529F-4FC7-8478-73F0696469D4

Q34664129-0961581D-3A89-4B63-B40C-CFD99C2B1B94

Q34664129-097D70C7-140D-4CBF-A830-C25756970143

Q34664129-0D77A657-AB55-4DBC-BBA7-5CF5572347DF

Q34664129-133CE2AF-0BCA-473A-8058-CB9BEEB357CE

Q34664129-1788CC75-64F8-4D6F-9E4E-C6DF3CD9FAEF

Q34664129-1F4B2A41-DA0D-4AAA-A6C9-6AFD06E0F85A

Q34664129-1FE0E145-5EB2-4626-8530-839F9FE90459

P304

Q34664129-145A30DB-2C93-4D9B-853C-BDEDE357DF93

P31

Q34664129-AA492BA4-9DFB-4518-95EE-446974448C59

P356

Q34664129-A8FC0A44-06E9-4B39-8570-001383BEDE44

P407

Q34664129-279A0E6E-A869-47DF-B4DF-027452A82CD2

P433

Q34664129-75C2FCA7-AC8D-4DC1-AB23-A45EA4A3BAE5

P478

Q34664129-D4F08AF8-4857-46D5-8E91-090E529FC04E

P577

Q34664129-FE630852-B438-4C82-899F-E7EB601D33E9

P5875

Q34664129-D4BD241C-E646-4BCB-9143-743D315BE113

P698

Q34664129-34782C0F-A300-45FE-A177-25A3A9BE230D

P921

Q34664129-97cee82e-4f8c-6cc9-d493-e3de6ecfb2be

P932

Q34664129-BB5861BF-EC57-4870-A374-283574B48DAC

P356

J.BBCAN.2014.07.007

P1433

Biochimica et Biophysica Acta

P1476

Personalized drug combinations ...... n HER2-positive breast cancer.

@en

P2093

Francois X Claret

http://www.w3.org/2001/XMLSchema#string

Mark X Sliwkowski

http://www.w3.org/2001/XMLSchema#string

Thuy Vu

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

P304

353-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBCAN.2014.07.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1846

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264314679

http://www.w3.org/2001/XMLSchema#string

P698

25065528

http://www.w3.org/2001/XMLSchema#string

P921

Her2-receptor positive breast cancer

P932

4261073

http://www.w3.org/2001/XMLSchema#string